Contineum, J&J's depression drug fails to meet mid-stage trial goal

CTNM•2026-09-14

Mid-stage trial misses primary goal

Contineum Therapeutics said on Monday an experimental depression drug it developed with Johnson & Johnson failed to meet the main goal of a mid-stage study.

Sept. 15 (Reuters) - Contineum Therapeutics CTNM.O said on Monday an experimental depression drug it developed with Johnson & Johnson JNJ.N failed to meet the main goal of a mid-stage study.

Contineum, J&J's depression drug fails to meet mid-stage trial goal

Mid-stage trial misses primary goal

Related News

Amazon closes £4.25 billion multi-tranche notes offering

EverCommerce files Form 3 for CEO Alexander Goor as beneficial owner

Live markets-US stocks end lower; chip stocks have biggest daily drop since July 1

Genasys extends Maran Partners term loan maturity to Oct. 30 after $800,000 repayment

Oracle announces BRL 0.28 dividend per unit, payable Oct. 30